Monson Jonathan 4
4 · BOSTON SCIENTIFIC CORP · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Boston Scientific (BSX) CFO Jonathan Monson Exercises Options, Receives Awards
What Happened
Jonathan Monson, EVP and Chief Financial Officer of Boston Scientific, exercised 1,154 derivative shares (options) on Feb 12, 2026, and had 573 shares withheld to cover tax obligations (573 x $74.12 = $42,471). On the same date he was granted awards/units totaling 39,662 shares (11,805 + 27,857) and an option grant that vests in future years. The exercise entries are recorded at $0.00 per share in the filing (typical for conversion/vesting entries), and the tax withholding shows a per-share value of $74.12.
Key Details
- Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (filed late by five days).
- Exercise/conversion: 1,154 shares (derivative exercise/conversion), listed at $0.00.
- Tax withholding/payment: 573 shares withheld at $74.12/share, total $42,471 (code F — tax withholding to cover liabilities).
- Awards granted: 11,805 RSUs (vesting beginning Feb 12, 2025 in four equal annual installments) and 27,857 RSUs (vesting beginning Feb 12, 2027 in four equal annual installments).
- Option grant: an option award was granted that vests in four equal annual installments beginning Feb 12, 2027.
- Shares owned after transaction: not specified in this filing.
- Footnotes: F1–F4 explain that RSUs convert to shares (one RSU = one share) and describe vesting schedules and the new option vesting terms.
- Filing timeliness: This Form 4 was filed late (transaction Feb 12; filing Feb 17). Late filings reduce transparency and may draw SEC scrutiny, but do not change the substance of the transactions reported.
Context
This filing reflects routine executive equity activity: an exercise/conversion and tax withholding (often part of a cashless exercise or withholding to satisfy tax obligations) combined with new equity awards and an option grant. The large items here are awards (RSUs and an option) that vest over multiple years — these are compensation grants rather than open-market purchases or sales. Such awards are common for executives and don't by themselves indicate the insider is buying or selling company stock in the market.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-12+1,154→ 36,443 total - Tax Payment
Common Stock
2026-02-12$74.12/sh−573$42,471→ 35,870 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-02-12−1,154→ 2,308 totalExp: 2028-02-12→ Common Stock (1,154 underlying) - Award
Restricted Stock Units
[F1][F3]2026-02-12+11,805→ 11,805 totalExp: 2030-02-12→ Common Stock (11,805 underlying) - Award
Stock Option (Right to Buy)
[F4]2026-02-12+27,857→ 27,857 totalExercise: $74.12Exp: 2036-02-12→ Common Stock (27,857 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- [F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.
- [F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.
- [F4]Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.